Filing Flows › Amneal Pharmaceuticals (AMRX) › Guidance history
Amneal Pharmaceuticals (AMRX) guidance history: what it guided and what it reported
Amneal Pharmaceuticals gave guidance in 9 earnings releases on file since Mar 1, 2024. Of 1 guided period since reported, it met or beat its own guidance once (100%). Revenue: 1 of 1, on average +7.5% against the guided midpoint. Its releases raised guidance 4 times and lowered it 3 times.
Revenue
Met or beat 1 of 1 periods (1 above, 0 within, 0 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $3.0B–$3.1B (Apr 22, 2026) | — | to be reported | — |
| FY2024 | $2.5B–$2.6B (Mar 1, 2024) | $2.8B | above the range | +7.5% |
Capital expenditures
The GAAP figure from the filings is shown for each period reported; it is not judged against the guide, which may leave items out (one-off payments, acquisitions).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2025 | $20.0M (May 2, 2025) → reaffirmed $20.0M (Aug 5, 2025) → reaffirmed $20.0M (Oct 30, 2025) | $70.1M (GAAP) | not judged | — |
| FY2024 | $60.0M–$70.0M (Mar 1, 2024) | $51.9M (GAAP) | not judged | — |
Operating cash flow
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $325M–$375M (Feb 27, 2026) | — | to be reported | — |
Adjusted EPS
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | −$2.00 (Apr 22, 2026) | — | to be reported | — |
| FY2024 | −$2.00 (Mar 1, 2024) | — | — | — |
The latest quarter
Amneal Pharmaceuticals, Q3 2026: revenue $863M (+10% year over year), operating margin 11.1%, net earnings $12.3M, operating cash flow $98.3M. The chart follows the revenue to costs, profit and cash.
Questions
Does Amneal Pharmaceuticals beat its guidance?
Amneal Pharmaceuticals gave guidance in 9 earnings releases on file since Mar 1, 2024. Of 1 guided period since reported, it met or beat its own guidance once (100%). Revenue: 1 of 1, on average +7.5% against the guided midpoint.
How often does Amneal Pharmaceuticals raise guidance?
Its earnings releases raised guidance 4 times and lowered it 3 times since Mar 1, 2024.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.